Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Company Deals

Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China

Fineline Cube Nov 6, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Company Deals

CORXEL Partners with WuXi STA for Sterile Nasal Spray Production

Fineline Cube Nov 6, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...

Company Drug

Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management

Fineline Cube Nov 6, 2023

Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...

Company Drug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Fineline Cube Nov 6, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Drug

AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination

Fineline Cube Nov 6, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...

Deals R&D

HKU and SIIDB Collaborate on Drug Development for Infectious Diseases

Fineline Cube Nov 6, 2023

The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting

Fineline Cube Nov 6, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...

Company Deals

XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics

Fineline Cube Nov 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement...

Company Drug

Zhejiang Huahai Pharmaceutical’s HB0052 Receives US FDA IND Approval for Solid Tumors

Fineline Cube Nov 6, 2023

IntroductionZhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...

Company Drug

BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE

Fineline Cube Nov 6, 2023

The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab)...

Company Drug

Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO

Fineline Cube Nov 6, 2023

Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study

Fineline Cube Nov 6, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has...

Company Deals

Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies

Fineline Cube Nov 3, 2023

Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the...

Company Deals

AbbVie Secures Option Agreement with Aldeyra Therapeutics for RASP Modulator Reproxalap

Fineline Cube Nov 3, 2023

AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a...

Company

Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales

Fineline Cube Nov 3, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...

Company Drug

Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia

Fineline Cube Nov 3, 2023

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase...

Company Deals Drug

Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals

Fineline Cube Nov 3, 2023

BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...

Company Drug

Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth

Fineline Cube Nov 3, 2023

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its...

Posts pagination

1 … 405 406 407 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.